Multiple Paths Can Lead to Cybersecurity Success 
Instruct3D Strengthens Additive Build Intelligence Message Following ICAM 2026 
Otto Group and Sereact Bring NVIDIA-Powered Physical AI to Returns Processing Strata Identity Joins Cloud Security Alliance to Advance Multi-Cloud Identity Interoperability
The Identity Orchestration Company will work with alliance members on initiatives for identity orchestration and…
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma Approved in China
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”)…
SELLAS Life Sciences’ Independent Data Monitoring Committee Recommends Galinpepimut-S REGAL Trial to Continue as Planned
NEW YORK, Dec. 08, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)…
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy
LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the…
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
Expands Commercialization Efforts in Areas with High Unmet Needs IRVINE, Calif., Dec. 08, 2022 (GLOBE…
AIM ImmunoTech Reports Positive Safety, Tolerability and Biological Activity Data for Intranasal Ampligen® (Rintatolimod) in Healthy Subjects
Intranasal administration of Ampligen demonstrated to be well-tolerated Based on data generated to date, Ampligen…
INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune™
Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) — INmune Bio, Inc. (NASDAQ: INMB) (“INMB” or “the…
AltruBio Hosting Research & Development Update on Immune Checkpoint Enhancer Platform for T Cell Mediated Immunological Diseases
The Company will Provide an Overview of its Immune Checkpoint Enhancer (ICE) Platform Clinical Proof-of-Concept…
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
Company also announces that Julia Haller, MD, is stepping down from its Board of Directors…
Baudax Bio Initiates Phase II Clinical Trial Evaluating BX1000 in Patients Undergoing Surgery
MALVERN, Pa., Dec. 08, 2022 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX) a pharmaceutical company…
Alimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan Agreement
ATLANTA, Dec. 08, 2022 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global…
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
Company to Announce Lead Program During Podium Presentation CAMBRIDGE, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE)…
Aligos Therapeutics Presents Nonclinical Data for its Coronavirus Therapeutic Program at the 2022 Respi DART Meeting
Coronavirus protease inhibitor, ALG-097558, has demonstrated antiviral activity in vivo and promising pan-coronavirus activity in…
Salarius Pharmaceuticals to Hold Conference Call to Discuss Recent Clinical and Preclinical Data on Lead Programs, Including Presentations at ASH
Conference Call to be Held on December 14th at 11:00 a.m. Eastern Time HOUSTON, Dec….
Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha
Media Release First 2,000L Manufacturing Run of its First-in-Class Soluble LAG-3 Protein Completed by WuXi…
Canary Medical Announces Introduction of Groundbreaking Orthopedic Analytic Platform
Canary Quantiles™ Recovery Curves Compare Observed Gait Performance versus Population Gait Performance During a Patient’s Recovery…
Digipath, Inc. Announces Revenue Increase of Almost 18% for the Fourth Quarter of Fiscal Year 2022
LAS VEGAS, NV, Dec. 08, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Digipath, Inc. (OTCQB:…
HCW Biologics Enters CRADA with National Cancer Institute
NCI Activated as Clinical Site for Phase 1b/2 Clinical Trial to Evaluate HCW9218 in Advanced Pancreatic…
Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO – IO) Annual Congress
– INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single…
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44%…